Expert Rev Ophthalmol. 2013;8(5):475-484. Together, these preclinical data indicate that both antibody and small kinase-based VEGF/PDGF antagonists are effective in animal models of pathologic ocular ...
VEGF, PDGF alpha, PDGF beta, and C-Kit expression are not independent survival predictors in stage D
Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI) No significant financial relationships to disclose. This ...
The receptors for vascular endothelial growth factor and platelet-derived growth factor (VEGFR-2 and PDGFR) play essential and complementary roles in angiogenesis, and combined inhibition of these ...
“The present study analyzed PDGFR and VEGFR expression in primary colon cancer tissues and CRC cell lines in order to better define their expression profiles. Furthermore, we analyzed putative PDGF ...
CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
Ophthotech Corp.'s potential $1 billion-plus, ex-U.S. deal with Novartis AG for Fovista, the antiplatelet-derived growth factor (PDGF) agent capable of enhancing the efficacy of anti-VEGF therapies in ...
PRINCETON, N.J., April 26 /PRNewswire/ -- Ophthotech Corp. ("Ophthotech"), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today ...
Platelet-derived growth factors (PDGFs) are mitogenic during early development, promoting the proliferation of undifferentiated mesenchymal cells and specific progenitor populations. At later ...
MARINA Trial (2006) Ranibizumab is effective in wet AMD (minimal adverse effects) Randomized trial resulted in FDA approval of ranibizumab, the current first-line treatment for wet AMD ANCHOR Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results